|
|
|
| Effect of Irbesartan Combined with Dapagliflozin on Vascular Elasticity in Elderly Patients with Isolated Systolic Hypertension |
| WANG Lu, CHEN Wei, ZHANG Yingfu |
| Henan General Hospital, Zhengzhou Henan 450002 |
|
|
|
|
Abstract 【Objective】To explore the effect of irbesartan combined with dapagliflozin on vascular elasticity in elderly patients with isolated systolic hypertension (ISH).【Methods】A total of 158 elderly ISH patients admitted to our hospital from May 2022 to June 2024 were selected and divided into the observation group and the control group by the random number table method, with 79 patients in each group. The control group was treated with irbesartan, and the observation group was treated with irbesartan combined with dapagliflozin. Both groups were treated for 24 weeks. Blood pressure levels (24-hour average diastolic blood pressure, 24-hour average systolic blood pressure), vascular elasticity [carotid-femoral pulse wave velocity (cfPWV), ankle-brachial index (ABI), pressure-strain elastic modulus (Ep)], serum inflammatory factors [high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α)] and the incidence of adverse reactions were compared between the two groups before and after treatment.【Results】After treatment, the 24-hour average systolic blood pressure of both groups was lower than that before treatment, and that of the observation group was lower than that of the control group, with a statistically significant difference (P<0.05). There was no statistically significant difference in the 24-hour average diastolic blood pressure between the two groups (P>0.05). After treatment, cfPWV and Ep in the observation group were lower than those in the control group, and ABI was higher than that in the control group, with statistically significant differences (P<0.05). After treatment, the levels of serum hs-CRP and TNF-α in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Irbesartan combined with dapagliflozin can effectively improve the vascular elasticity of elderly ISH patients, significantly reduce systolic blood pressure, inhibit the inflammatory response, and has good safety, which has clinical promotion value.
|
|
Received: 21 May 2025
|
|
|
|
|
|
[1] 葛昭,刘春香,杨志华,等. 中医药治疗老年单纯收缩期高血压的临床研究结局指标分析[J].天津中医药大学学报,2024,43(3):225-230.
[2] 张辉,张媛,喻成,等. 子午流注理论指导择时点穴按压联合中药沐足治疗阴虚阳亢型老年单纯收缩期高血压疗效及对血管弹性的影响[J].现代中西医结合杂志,2025,34(2):227-231.
[3] 李宝娟,常欣,王昆. SGLT2i联合ARB对合并2型糖尿病的老年单纯收缩期高血压患者血压的影响分析[J].中国循证心血管医学杂志,2023,15(9):1092-1095.
[4] 沈燕雯. 小剂量氢氯噻嗪辅助治疗老年单纯收缩期高血压的效果观察及其对患者血清学的影响[J].贵州医药,2022,46(4):538-539.
[5] 王文静. 厄贝沙坦氢氯噻嗪联合金匮肾气丸治疗高血压慢性心力衰竭患者的临床效果及对NLRP3/NF-κB通路的影响[J].医学临床研究,2023,40(8):1225-1228.
[6] 张沙沙,赵贤淑,刘丽,等. 钠-葡萄糖协同转运蛋白2抑制剂通过调控沉默信息调节蛋白1/线粒体解偶联蛋白2信号通路对2型糖尿病合并心力衰竭大鼠心功能影响的研究[J].中国糖尿病杂志,2025,33(3):221-226.
[7] 中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[8] 马镇. 丹参川芎嗪注射液联合厄贝沙坦分散片治疗原发性高血压的临床效果[J].中国医学创新,2024,21(9):21-25.
[9] 吴凌恒,陈建雄,张梦娇,等. 糖尿病患者动脉弹性与心血管耦联关系的初步研究[J].临床超声医学杂志,2023,25(4):259-264.
[10] 李明峰,戴晶,张金波,等. 基于超极速脉搏波技术的高血压血管弹性功能损伤因素分析[J].实用临床医药杂志,2022,26(17):29-36.
[11] 别必柯,张瑶. 真实世界钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭患者预后影响的分析研究[J].中国心血管病研究,2024,22(11):1013-1020.
[12] 史丽,胡婷婷,李红,等. 达格列净对糖尿病大鼠血管内皮功能及PTEN/PI3K/Akt信号通路的影响[J].中国现代医学杂志,2022,32(10):13-17.
[13] 葛学婉,吴妍,郭沫,等. SGLT-2i临床心血管保护作用及机制研究进展[J].中国药理学通报,2025,41(3):401-406.
[14] LI M, YI T, FAN F, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis[J].Cardiovasc Diabetol,2022,21(1):139.
[15] ANDREEA MM, SURABHI S, RAZVAN-IONUT P, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: Harms or unexpected benefits?[J].Medicina(Kaunas),2023,59(4):742. |
|
|
|
2025, Vol. 42 
